Health Catalyst (NASDAQ:HCAT) Price Target Cut to $10.00 by Analysts at Citigroup

Health Catalyst (NASDAQ:HCAT - Free Report) had its target price cut by Citigroup from $10.50 to $10.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages also recently commented on HCAT. Royal Bank of Canada lifted their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Stephens lifted their price target on Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Thursday, November 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Evercore ISI lifted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 8th. Finally, KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price target for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.45.

Health Catalyst Stock Performance

Shares of Health Catalyst stock traded down $0.47 during trading on Friday, hitting $6.89. 477,428 shares of the company's stock were exchanged, compared to its average volume of 547,021. The business has a 50-day simple moving average of $7.79 and a 200-day simple moving average of $7.52. The stock has a market capitalization of $419.24 million, a price-to-earnings ratio of -5.10 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. The business's revenue for the quarter was up 3.5% on a year-over-year basis. On average, research analysts forecast that Health Catalyst will post -0.33 EPS for the current year.

Insider Buying and Selling at Health Catalyst

In related news, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the completion of the transaction, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. This trade represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the sale, the insider now owns 236,950 shares in the company, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 76,051 shares of company stock valued at $612,614 in the last three months. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC acquired a new stake in Health Catalyst in the third quarter valued at $34,000. Quarry LP raised its position in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. nVerses Capital LLC purchased a new stake in Health Catalyst during the third quarter worth approximately $59,000. Quadrature Capital Ltd purchased a new stake in Health Catalyst during the third quarter worth approximately $84,000. Finally, Mackenzie Financial Corp purchased a new position in Health Catalyst in the second quarter valued at approximately $70,000. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.